Dr. Yochai Wolf received his PhD in Immunology at the Weizmann Institute of Science, studying the role of macrophages in health and disease. He then decided to focus his career on cancer immunology and started his first postdoctoral training, also at the Weizmann Institute, studying the interactions between tumor heterogeneity and cancer immunology. He then moved to Boston, MA, USA, for his second postdoctoral training at Harvard Medical School and Brigham and Women’s hospital, studying the role of the novel checkpoint molecule TIM-3 in cancer and autoimmunity. Dr. Wolf have joined Sheba Medical Center and is now the Head of the research and development at the Ella Lemelbaum Institute for immuno-oncology and melanoma, a world-class center for cancer therapeutics, clinical trials, and research.